Summary
[HengruiMedicine:HR19003patchwillstartclinicaltrialsinthenearfuture]On August 5, Hengrui Medicine announced that the company has recently received the approval and issuance of the “Drug Clinical Trial Approval Notice” for HR19003 patch by the National Medical Products Administration. Clinical trials will be carried out in the near future. The drug can penetrate the skin around the peripheral nerves of the drug site, block the sodium ion channel on the nerve cell membrane, inhibit the flow of sodium ions into the nerve fiber cell membrane, block nerve excitement and conduction, produce reversible local block, so as to achieve analgesia and anesthesia Effect. (Interface News)
August 5,Hengrui Medicineannouncement, The company has recently received the “Notice of Drug Clinical Trial Approval” for the HR19003 patch approved by the National Medical Products Administration, and clinical trials will be launched in the near future. The drug can penetrate the skin around the peripheral nerves of the drug site, block the sodium ion channel on the nerve cell membrane, inhibit the flow of sodium ions into the nerve fiber cell membrane, block nerve excitement and conduction, produce reversible local block, so as to achieve analgesia and anesthesia Effect.
(Article Source: Interface News)
.